抄録
A man in his 70s was admitted to an intensive care unit with severe COVID-19 and treated with dexamethasone and tocilizumab. After recovery from COVID-19, he developed Clostridium butyricum bacteraemia and non-occlusive mesenteric ischaemia, with fatal outcome. He had been prescribed C. butyricum MIYAIRI 588 fine granules as probiotics for a month. The genome sequences of the C. butyricum isolate from the blood culture and C. butyricum MIYAIRI 588 fine granules were identical by single nucleotide polymorphism analysis. This is the first case of definitive probiotics-related C. butyricum bacteraemia after treatment of severe COVID-19.
本文言語 | 英語 |
---|---|
ジャーナル | BMJ Case Reports |
巻 | 17 |
号 | 8 |
DOI | |
出版ステータス | 出版済み - 03-08-2024 |
外部発表 | はい |
All Science Journal Classification (ASJC) codes
- 医学一般